Berlin – For decades, the experience of pain has been largely viewed through a gender-neutral lens, with medical research often failing to adequately account for biological differences between men and women. However, a growing body of evidence, and a new study published February 20, 2026, in the journal Science Immunology, is challenging this assumption. The research reveals a potential biological basis for why women experience chronic pain more intensely and for longer durations than men, pointing to a key role played by the immune system and hormone regulation. This discovery not only validates the lived experiences of millions of women but as well opens avenues for developing more targeted and effective pain management strategies.
Chronic pain, defined as pain lasting more than three months, affects a significant portion of the global population. According to the International Association for the Study of Pain (IASP), an estimated 20% of adults worldwide suffer from chronic pain, with substantial socioeconomic impacts due to lost productivity and healthcare costs. The IASP estimates the global cost of chronic pain exceeds $560 billion annually. While pain is subjective, studies consistently demonstrate that women are disproportionately affected, and their pain is often more debilitating. This disparity has historically been dismissed by some as psychological or emotional, but the new research provides compelling evidence of a concrete biological mechanism at play.
The study, led by researchers at Michigan State University (MSU), focuses on a specific type of immune cell called monocytes. These cells are regulated by hormones, including testosterone, and play a crucial role in modulating the body’s inflammatory response. Researchers discovered that monocytes release a molecule – interleukin-10, or IL-10 – that effectively “switches off” pain signals. Crucially, they found that these pain-dampening monocytes are more active in males due to higher levels of testosterone. In contrast, women exhibit less activity in these cells, leading to a prolonged pain experience and slower recovery.
The Immune System’s Role in Sex-Specific Pain Responses
The research team, including Geoffroy Laumet, associate professor of physiology at MSU, and Jaewon Sim, a former student in his laboratory, initially set out to understand the broader mechanisms by which the immune system influences pain resolution. Their investigations, detailed in Science Immunology, unexpectedly revealed the significant impact of sex hormones on monocyte function. “What we demonstrated is a real biological mechanism of immune cells. It’s not in the mind,” Laumet stated, emphasizing the objective nature of the findings. France 24 reported on the study’s findings, highlighting the potential for new therapeutic approaches.
The study employed both animal models – specifically, mice – and human subjects to validate their findings. The researchers observed a consistent pattern: pain persisted longer in female mice, and their monocytes exhibited reduced IL-10 production compared to their male counterparts. These results were mirrored in human patients, further strengthening the evidence for a sex-specific immune response to pain. This dual approach, combining preclinical and clinical data, enhances the reliability and translational potential of the research.
The implications of this discovery extend beyond simply acknowledging the difference in pain experience between sexes. It suggests that manipulating monocyte activity could offer a novel therapeutic strategy for chronic pain management. Currently, many pain treatments rely on opioid medications, which carry a high risk of addiction and adverse side effects. Finding alternative, non-opioid approaches is a critical priority in healthcare. The potential to boost IL-10 production or enhance monocyte function in women could provide a more targeted and safer way to alleviate chronic pain.
Understanding Interleukin-10 and Pain Modulation
Interleukin-10 (IL-10) is a potent anti-inflammatory cytokine – a signaling molecule that regulates immune responses. It plays a crucial role in resolving inflammation and suppressing pain signals. When the body experiences an injury or inflammation, the immune system is activated, leading to the release of various cytokines. IL-10 acts as a counterbalance, dampening the inflammatory response and promoting tissue repair. In the context of chronic pain, a deficiency in IL-10 production or impaired monocyte function can contribute to persistent inflammation and heightened pain sensitivity.
The study’s findings suggest that hormonal differences between men and women directly impact IL-10 production by monocytes. Testosterone, a primary male sex hormone, appears to enhance monocyte activity and IL-10 release. Conversely, lower testosterone levels in women, coupled with the influence of other hormones like estrogen, may contribute to reduced monocyte function and diminished IL-10 production. This hormonal interplay creates a biological basis for the observed sex differences in pain perception and duration.
Potential Therapeutic Avenues and Future Research
Laumet envisions a future where therapies can be tailored to specifically address the immune-related mechanisms underlying chronic pain. “Long term, People can investigate how to stimulate the monocytes and increase the production of IL-10 to boost the body’s ability to resolve pain,” he explained. In the short term, he suggests that topical testosterone could be a viable option for localized pain relief. However, he cautions that further research is needed to determine the optimal dosage and delivery method for testosterone therapy.
Elora Midavaine, a researcher at the University of California, San Francisco, who studies chronic pain but was not involved in the MSU study, lauded the findings as a significant contribution to the field. She emphasized that the research aligns with a broader movement focused on the intersection of neuroscience, immunology, and endocrinology. “This has the potential to advance our understanding of chronic pain in women,” Midavaine stated. Telemundo News also covered the study, noting the historical tendency to dismiss women’s pain as exaggerated.
The study also highlights the importance of recognizing and addressing the systemic biases that have historically minimized women’s pain experiences. For too long, women have been told their pain is “all in their head” or that they have a lower pain tolerance than men. This research provides concrete evidence that these perceptions are inaccurate and harmful. It underscores the need for healthcare providers to take women’s pain seriously and to consider the biological factors that may contribute to their experience.
the findings emphasize the need for more inclusive research in the field of pain management. Historically, clinical trials have often been dominated by male participants, leading to a limited understanding of how pain affects women differently. Increasing the representation of women in research studies is crucial for developing effective and equitable pain treatments.
Key Takeaways
- Women experience chronic pain more intensely and for longer durations than men, a disparity now linked to biological factors.
- Monocytes, immune cells regulated by hormones, play a key role in modulating pain signals through the production of interleukin-10 (IL-10).
- Testosterone enhances monocyte activity and IL-10 release, explaining why men tend to have a more robust pain-dampening response.
- The research opens new avenues for developing targeted, non-opioid pain treatments that address the underlying immune mechanisms.
- Recognizing and addressing systemic biases in pain research and healthcare is crucial for ensuring equitable care for women.
Looking ahead, researchers plan to investigate the potential of various therapeutic interventions to stimulate monocyte activity and boost IL-10 production in women. Further studies are also needed to explore the role of other hormones and immune factors in sex-specific pain responses. The ultimate goal is to develop personalized pain management strategies that are tailored to the unique biological needs of both men and women.
The findings from MSU represent a significant step forward in our understanding of chronic pain and its complex interplay with the immune system and hormonal regulation. As research continues, we can anticipate the development of more effective and equitable pain treatments that will improve the quality of life for millions of people worldwide. The next phase of research, expected to begin in the third quarter of 2026, will focus on clinical trials to test the efficacy of targeted immunotherapies for chronic pain in women.
What are your thoughts on this groundbreaking research? Share your experiences and perspectives in the comments below, and please share this article with anyone who might uncover it helpful.